top of page

CAPRELSA (vandetanib) is a kinase inhibitor used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. CAPRELSA can also be used to treat a patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. It is approved by the Food and Drug Administration (FDA).

Manufacturer : AstraZeneca


    • 30 tablets per bottle
bottom of page